Prolonged Response to Oral Gefitinib, Cyclophophamide, and Topotecan in Heavily Pretreated Relapsed Stage 4 Neuroblastoma
| Autor: | Maria Antonietta De Ioris, Alessandro Jenkner, Giuseppe Milano, Alberto Donfrancesco, Ilaria Ilari, Aurora Castellano, Carlo Dominici, Clementina De Laurentis, Maria Carmen Garganese |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Oncology
medicine.medical_specialty Cyclophosphamide medicine.medical_treatment Adrenal Gland Neoplasms Administration Oral Fixed dose Neuroblastoma Gefitinib Recurrence Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Stage (cooking) Radionuclide Imaging Chemotherapy business.industry Hematology medicine.disease Treatment Outcome Child Preschool Pediatrics Perinatology and Child Health Quinazolines Female Topotecan Compassionate Treatment business medicine.drug |
| Zdroj: | Journal of Pediatric Hematology/Oncology. 29:799-803 |
| ISSN: | 1077-4114 |
| Popis: | A girl with metastatic neuroblastoma diagnosed at 4 years of age experienced an early disseminated relapse after high-dose chemotherapy. After reinduction, compassionate treatment with gefitinib (250 mg/d fixed dose) with oral topotecan (0.8 mg/m(2)/d) and cyclophosphamide (50 mg/m(2)/d) for 14 consecutive days, each course repeated every 28 days, was administered. Complete marrow clearance and metaiodobenzylguanidine response were achieved after 4 courses. After the first course, topotecan and cyclophosphamide were reduced by 25% for grade 4 hematologic toxicity. Subsequent courses were well tolerated. The girl remained progression free for 27 months. This combination may represent a viable therapeutic option and deserves further evaluation in resistant neuroblastoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|